

Anti-Murine IL-1 β Antibody

Catalog # ABG10243

Product Information

Application	WB, IHC, E
Reactivity	Mouse
Host	Rabbit
Clonality	Polyclonal

Additional Information

Preparation	Produced from sera of rabbits pre-immunized with highly pure (>98%) recombinant mIL-1 β . Anti-Murine IL-1 β specific antibody was purified by affinity chromatography employing immobilized mIL-1 β matrix.
WesternBlot	To detect mIL-1 β by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 μ g/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant mIL-1 β is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.
Sandwich	To detect mIL-1 β by sandwich ELISA (using 100 μ l/well antibody solution) a concentration of 0.5 - 2.0 μ g/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with BioGems' Biotinylated Anti-Murine IL-1 β (61-001BBT) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant mIL-1 β .
Immunohistochemistry	This antibody stained colchicine injected mouse brain (polymorph layer of the dentate gyrus) tissue. The primary antibody was incubated at 0.5 μ g/ml overnight at 4 °C. This was followed by a peroxidase conjugated secondary antibody and then a fluorescein Tyramide Signal Amplification (TSA™) reagent. Optimal concentrations and conditions may vary. Profiling group, SciLifeLab Stockholm.
Neutralization	To yield one-half maximal inhibition [ND ₅₀] of the biological activity of mIL-1 β (10 pg/ml), a concentration of 0.57-0.86 μ g/ml of this antibody is required.
Formulation	A sterile filtered antibody solution was lyophilized from PBS, pH 7.2.
Reconstitution	Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.
Storage	-20°C
Precautions	Anti-Murine IL-1 β Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.